Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the effects of the combination of
bevacizumab, vinorelbine, and trastuzumab on participants and their cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Harold J. Burstein, MD, PhD
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Hartford Hospital Lowell General Hospital Massachusetts General Hospital New Hampshire Oncology-Hematology PA